Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Chronic Granulomatous Disease-Associated Colitis
NCT05333471Phase 2Recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2022
- Primary completion
- Mar 2027
- Modality
- Biologic (Biologic)
- Countries
- 1
01
Overview
A Phase 2 trial of MTP-101LF in chronic granulomatous disease (CGD), sponsored by National Institute of Allergy and Infectious Diseases. Started Aug 2022; status: recruiting.
02
Drugs
MTP-101LF
03
Conditions
chronic granulomatous disease (CGD)
Beyond the preview
Go deeper on NCT05333471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05333471.